[go: up one dir, main page]

SG11202011304QA - Compositions comprising pcsk9-binding molecules and methods of use - Google Patents

Compositions comprising pcsk9-binding molecules and methods of use

Info

Publication number
SG11202011304QA
SG11202011304QA SG11202011304QA SG11202011304QA SG11202011304QA SG 11202011304Q A SG11202011304Q A SG 11202011304QA SG 11202011304Q A SG11202011304Q A SG 11202011304QA SG 11202011304Q A SG11202011304Q A SG 11202011304QA SG 11202011304Q A SG11202011304Q A SG 11202011304QA
Authority
SG
Singapore
Prior art keywords
pcsk9
compositions
methods
binding molecules
molecules
Prior art date
Application number
SG11202011304QA
Inventor
Tracy Mitchell
Richard Mealey
Original Assignee
Lib Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lib Therapeutics Llc filed Critical Lib Therapeutics Llc
Publication of SG11202011304QA publication Critical patent/SG11202011304QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG11202011304QA 2018-05-16 2019-05-16 Compositions comprising pcsk9-binding molecules and methods of use SG11202011304QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862672187P 2018-05-16 2018-05-16
PCT/US2019/032710 WO2019222529A1 (en) 2018-05-16 2019-05-16 Compositions comprising pcsk9-binding molecules and methods of use

Publications (1)

Publication Number Publication Date
SG11202011304QA true SG11202011304QA (en) 2020-12-30

Family

ID=68540981

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011304QA SG11202011304QA (en) 2018-05-16 2019-05-16 Compositions comprising pcsk9-binding molecules and methods of use

Country Status (14)

Country Link
US (3) US10738102B2 (en)
EP (1) EP3793612A4 (en)
JP (1) JP7515406B2 (en)
KR (1) KR20210010890A (en)
CN (1) CN112423790B (en)
AU (1) AU2019269617A1 (en)
BR (1) BR112020023344A2 (en)
CA (1) CA3115341A1 (en)
EA (1) EA202092778A1 (en)
IL (1) IL278710B1 (en)
MX (1) MX2020012214A (en)
SG (1) SG11202011304QA (en)
WO (1) WO2019222529A1 (en)
ZA (1) ZA202007107B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7515406B2 (en) * 2018-05-16 2024-07-12 エルアイビー セラピューティクス インコーポレイテッド Compositions Comprising PCSK9 Binding Molecules and Methods of Use Thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009238550B2 (en) * 2008-04-23 2014-11-27 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 ( PCSK9) variants and uses thereof
EP2558491B1 (en) * 2010-04-13 2018-07-04 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind pcsk9
RU2604139C2 (en) * 2011-01-28 2016-12-10 Санофи Байотекнолоджи Pharmaceutical compositions containing antibodies to human pcsk9
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US20160152686A1 (en) * 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
MX2015012420A (en) * 2013-03-14 2016-06-02 Daiichi Sankyo Co Ltd Novel binding proteins for pcsk9.
ES2898273T3 (en) * 2014-03-20 2022-03-04 Bristol Myers Squibb Co Molecules with a structure based on stabilized fibronectin
EA202090216A3 (en) * 2014-03-20 2020-07-31 Бристол-Майерс Сквибб Компани BINDERS SERUM ALBUMIN DOMAINS FIBRONECTIN TYPE III
KR20240093725A (en) 2015-03-12 2024-06-24 메디뮨 엘엘씨 Method of purifying albumin-fusion proteins
JP7515406B2 (en) * 2018-05-16 2024-07-12 エルアイビー セラピューティクス インコーポレイテッド Compositions Comprising PCSK9 Binding Molecules and Methods of Use Thereof
WO2022268214A1 (en) * 2021-06-25 2022-12-29 甘李药业股份有限公司 Pharmaceutical composition of pcsk9 inhibitor and glp-1 receptor agonist

Also Published As

Publication number Publication date
US20210002350A1 (en) 2021-01-07
IL278710A (en) 2021-01-31
CN112423790A (en) 2021-02-26
MX2020012214A (en) 2021-03-31
WO2019222529A1 (en) 2019-11-21
JP2021523214A (en) 2021-09-02
AU2019269617A8 (en) 2020-12-17
US20200071386A1 (en) 2020-03-05
BR112020023344A2 (en) 2021-02-09
ZA202007107B (en) 2022-03-30
KR20210010890A (en) 2021-01-28
CA3115341A1 (en) 2019-11-21
JP7515406B2 (en) 2024-07-12
EP3793612A1 (en) 2021-03-24
AU2019269617A1 (en) 2020-12-03
IL278710B1 (en) 2025-05-01
EA202092778A1 (en) 2021-05-27
CN112423790B (en) 2025-05-16
EP3793612A4 (en) 2022-03-02
US10738102B2 (en) 2020-08-11
US20230295270A1 (en) 2023-09-21
US11692021B2 (en) 2023-07-04

Similar Documents

Publication Publication Date Title
IL274276A (en) Casz compositions and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
IL277889A (en) Oligonucleotide compositions and methods of use thereof
SG11202010131QA (en) Oligonucleotide compositions and methods of use thereof
ZA201906169B (en) Synthekine compositions and methods of use
IL276135A (en) Compositions and methods of use
ZA201903165B (en) Coating compositions and methods of use thereof
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL283782A (en) Anellosomes and methods of use
GB202105087D0 (en) Microbial compositions and methods of use
IL282939A (en) Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
IL265761A (en) Terlipressin compositions and their methods of use
ZA202000502B (en) Cosmetic compositions and methods of use
IL282533A (en) Oligosaccharide compositions and methods of use thereof
GB2568562B (en) Moldable compositions and methods of using thereof
IL274563A (en) Methods of using and compositions containing dulaglutide
IL274433A (en) Fulvestrant formulations and methods of their use
ZA202007107B (en) Compositions comprising pcsk9-binding molecules and methods of use
EP3484441A4 (en) Glycolipid compositions and methods of use
IL261794A (en) Compositions and methods of their use
GB201710491D0 (en) Composition and methods of treatment
HK40049616A (en) Compositions comprising pcsk9-binding molecules and methods of use
HK40065278A (en) Nanotransposon compositions and methods of use
HK40036149A (en) Cas12c compositions and methods of use